25
May
2020
Author: CoryTraina
27
Apr
2020
Bionest
Actions Around Drug Pricing Centering on Insulin
An increasing number of diabetes patients face affordability challenges for their insulin. How are pharma companies and the government responding?
2
Mar
2020
Bionest
New Treatment Options for Hemoglobin-Based Blood Disorders
Sickle cell disease is a group of inherited disorders that affects hemoglobin, the oxygen-carrying protein in red blood cells (RBCs), and causes these cells to distort in shape at low oxygen levels. This condition affects 1 in 500…
2
Mar
2020
Bionest
New Treatment Options for Hemoglobin-Based Blood Disorders
Sickle cell disease is a group of inherited disorders that affects hemoglobin, the oxygen-carrying protein in red blood cells (RBCs), and causes these cells to distort in shape at low oxygen levels. This condition affects 1 in 500 Americans of African descent and 1 in 1,000-1,400 of Hispanic descent, as well as millions...
17
Feb
2020
Bionest
New Treatments for Alzheimer’s Disease? Maybe.
The Alzheimer’s Association estimates that nearly six million Americans are living with the disease, a number that is expected to rise to 14 million by 2050. Marketed drugs such as memantine and donepezil modestly slow memory loss in some…
11
Nov
2019
Bionest
ESMO 2019: Translating Science into Better Cancer Care
The field of oncology has seen a number of significant advances in recent years. The considerable number of positive reports from the 2019 Congress of the European Society for Medical Oncology (ESMO) last month clearly reflected the meeting’s theme — the translation of scientific advances into better cancer care. AstraZeneca/Merck was one of stars...
4
Nov
2019
Bionest
Psychedelic Drug Research Making a Comeback
In the 1950s and early 1960s, researchers within both academic and governmental institutions extensively investigated the clinical potential of psychedelic drugs, notably both LSD and psilocybin, the psychoactive substance in “magic mushrooms.” This early research aimed to understand the biological underpinnings of schizophrenia and to find new treatments for psychological disorders such as depression, anxiety...
28
Oct
2019
Bionest
Long Awaited CMS Rules on Medicare Coverage for CAR-T Therapies
In August, the Centers for Medicare and Medicaid Services (CMS) finalized long-sought rules framing the coverage of chimeric antigen receptor T-cell (CAR-T) treatments. Two CAR-T therapeutics are currently on the market: Gilead’s Yescarta and Novartis’ Kymriah, both approved for diffuse large B-cell lymphoma (DLBCL) with the latter also approved for acute lymphocytic leukemia (ALL). Under...
21
Oct
2019
Bionest
New Strategies Against a Hard-to-Treat Killer — Pancreatic Cancer
Pancreatic cancer was the third leading cause of cancer-related death in the United States in 2018. This year, experts estimate that 56,770 new cases will be diagnosed and 45,750 deaths will be recorded. Pancreatic cancer is especially lethal because in its early stages, when the disease is easiest to treat, patients are usually asymptomatic. The disease...
14
Oct
2019